Back to Studies

IMPAACT 2041

Phase IV Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir (GLE/PIB) in People with Hepatitis C During Pregnancy and Postpartum

IND Number

TBD

Clinical Trials Link

TBD

Summary

IMPAACT 2041 is a Phase IV, open label, non-randomized study of glecaprevir/gibrentasvir‎ (GLE/PIB) for the treatment of Hepatitis C virus (HCV) during pregnancy and postpartum. The study is designed to evaluate the pharmacokinetics and safety of GLE/PIB during pregnancy and postpartum, and will follow pregnant people and their infants through three months postpartum. 

Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...